PCI Beats Medical Tx in Stable Ischemic Heart Disease

This article originally appeared here.
Share this content:
PCI Beats Medical Tx in Stable Ischemic Heart Disease
PCI Beats Medical Tx in Stable Ischemic Heart Disease

WEDNESDAY, May 6, 2015 (HealthDay News) -- For patients with stable ischemic heart disease (SIHD) and objective evidence of ischemia, percutaneous coronary intervention (PCI) is associated with lower mortality than medical therapy (MT), according to research published in the May 1 issue of The American Journal of Cardiology.

Hemal Gada, M.D., M.B.A., from the Rutgers Robert Wood Johnson Medical School in New Brunswick, N.J., and colleagues examined whether PCI improved mortality versus MT in patients with objective evidence of ischemia assessed using noninvasive imaging or its invasive equivalent. The authors performed a systematic review and meta-analysis of data from three randomized controlled trials involving 1,557 patients followed for an average of three years.

The researchers found that PCI correlated with lower mortality versus MT (hazard ratio, 0.52; P = 0.02). In the trials included in the meta-analysis there was no evidence of study heterogeneity or bias.

"In conclusion, this study provides insight into the management of a higher-risk SIHD population that is the focus of the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths